Strategic Partnership Boosts iPSC-Derived Therapeutic Development
Theragent Inc., a leader in cell- and tissue-based therapies, has announced a partnership with Pluristyx Inc., a biotech specializing in induced Pluripotent Stem Cell (iPSC) products. This collaboration aims to provide a comprehensive pathway from iPSC derivation to the commercial production of iPSC-derived drug products, promising a streamlined approach to therapeutic development. Under the partnership, […]